cas 1207351-15-2|| where to buy 5-ethynyl-1H-pyrazolo[3,4-b]pyridine

Produktname:5-ethynyl-1H-pyrazolo[3,4-b]pyridine

IUPAC Name:5-ethynyl-1H-pyrazolo[3,4-b]pyridine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM111790-100mg	in stock	ǙŮ
CM111790-250mg	in stock	ǸƴŮ
CM111790-1g	in stock	ƈǙǸ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1207351-15-2 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1207351-15-2; Molekulare Formel:C8H5N3; Schmelzpunkt:-; SMILES-Code:C#CC1=CN=C(NN=C2)C2=C1; Dichte:

: Katalognummer:CM111790; Molekulargewicht:143.15; Siedepunkt:; Mdl-Nr.:MFCD22187975; Lagerung:

: Pyrazolopyridines; Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

: Olverembatinib; Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.